NASDAQ: NVCN
TSX: NVC
VANCOUVER, Oct. 26, 2016 /PRNewswire/ - Neovasc Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX:
NVC) outlined today its notable presentations at the upcoming
annual Transcatheter Cardiovascular Therapeutics (TCT) symposium,
the world's largest educational meeting specializing in
interventional cardiovascular medicine in Washington, DC from October 29 to November 2, 2016.
On October 31, Dr. Anson Cheung will be providing an update on the
Tiara transcatheter mitral valve clinical program. Tiara
devices are currently being implanted under compassionate use in
several geographies, as well as in the TIARA-I Early Feasibility
Trial, a multinational, multicenter trial being conducted in the
US, Europe and Canada. The trial is assessing the safety and
performance of the Tiara mitral valve system and the implantation
procedure in high-risk surgical patients suffering from severe
mitral regurgitation (MR).
Also on October 31, Dr.
Gregg Stone will be highlighting
Reducer's clinical results in treating refractory angina.
Reducer, CE-marked in Europe, is a
medical device that provides relief of severe angina symptoms by
increasing pressure in the coronary sinus, thus redistributing
blood flow into the ischemic heart muscle. Placement of the Reducer
is performed using a minimally invasive transvenous procedure that
is similar to implanting a coronary stent and is completed in
approximately 20 minutes.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products in development
include the Tiara™, for the transcatheter treatment of mitral valve
disease and the Neovasc Reducer™ for the treatment of refractory
angina. The Company also sells a line of advanced biological tissue
products that are used as key components in third-party medical
products including transcatheter heart valves. For more
information, visit: www.neovasc.com.
SOURCE Neovasc Inc.